Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

(2019) Peter J Goadsby et al.   BRAIN

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

Nocebo effects: more investigation is needed

(2018) Fabrizio Benedetti et al.   Expert Opinion On Drug Safety

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Lasmiditan is an effective acute treatment for migraine

(2018) Bernice Kuca et al.   NEUROLOGY

Placebo and its evil twin, nocebo

(2016) Michael Glick   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

To Tell the Truth, the Whole Truth, May Do Patients Harm: The Problem of the Nocebo Effect for Informed Consent

(2012) Rebecca Erwin Wells et al.   AMERICAN JOURNAL OF BIOETHICS

The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

(2012) Peer C. Tfelt-Hansen et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

(2012) Markus Färkkilä et al.   LANCET NEUROLOGY

The Effect of Treatment Expectation on Drug Efficacy: Imaging the Analgesic Benefit of the Opioid Remifentanil

(2011) U. Bingel et al.   Science Translational Medicine

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial

(2010) Michel D Ferrari et al.   CEPHALALGIA